DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Mission Biocapital
Mission Biocapital
venture manager, reported GAV $186M across 2 vehicles
Importance
41
elevated
Active deployment
55
elevated
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
20
moderate
Identity and regulatory footprint
- Headquarters
- Cambridge, MAadviserinfo.sec.gov
- Office address
- ONE MAIN STREET, SUITE 1100, Cambridge, MA, 02142adviserinfo.sec.gov
- Business phone
- 508-507-0934adviserinfo.sec.gov
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 26, 2026
- Private funds reported
- 3 (3 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $409Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- info@missionbiocapital.commissionbiocapital.compublished by the subject
- business phone
- 617-812-3334adviserinfo.sec.govpublished by the subject
- business phone
- 508-507-0934adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
52 observed deals
Stated (the firm’s website)
- Sectors
- ai
- Stages
- not stated or not yet read
- Geography
- uk
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 83%Biotechnology 6%Other 4%Pharmaceuticals 4%Other Health Care 4%
lead rate 0%follow-on rate 0%new logos, 12 months 51
Funds and vehicles
2 reported, 1 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Mission BioCapital VI LP | Fund | 2024 form d first sale | Fundraising | unknown | unknown | $144M | Nov 14, 2025 |
| Bioinnovation Capital I LP | Fund | 2016 form d first sale | Harvest | $186M Mar 28, 2024 | 37 | $65.6M | Feb 15, 2017 |
| Mission Biocapital V LP | Fund | 2020 adv first reported | Wound down | $265M Mar 24, 2022 | 128 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
30 current, 5 departed
Cassidy Blundell
AnalystInvestment Analyst
Chaya Patel
AssociateInvestment Associate
Douglas Kingsley Crawford
General partnerMember, Class A Member Of Bioinnovation Capital I Gp Llc · since Apr 1, 2022
Eric W. Linsley
General partnerManager; Class A Member Of Bioinnovation Capital I, Gp Llc · since Apr 1, 2016
Johannes Fruehauf
General partnerClass A Member Of Bioinnovation Capital I, Gp Llc · since Apr 1, 2016
Linda Eng
General partnerGeneral Partner
Peter D. Parker
General partnerManager, Class A Member Bioinnovation Capital I, Gp Llc, · since Apr 1, 2016
Samar Jahan
General partnerGeneral Partner
Steven Webb Tregay
General partnerGeneral Partner And Director Of Bioinnovation Management Llc · since Nov 1, 2019
Susie Harborth
General partnerClass A Member Of Bioinnovation Capital I, Gp Llc · since Apr 1, 2016
Loretta Mcclary
Managing partnerManaging General Partner
Sarika Temme-Bapat
Managing partnerManaging General Partner
Steve Tregay
Managing partnerManaging General Partner
Zach Collins
Managing partnerManaging General Partner
Clay Rowland
Operating partnerOperating Partner
Platinum Program
OtherPlatinum Program Portfolio
Shared Labs
OtherPortfolio
Chris Carlin
PartnerPartner
Johannes Fruehauf
PartnerPartner
Robert Blazej
PartnerPartner
Christopher Taylor Carlin
Platform and operationsChief Compliance Officer And Coo Of Bioinnovation Management Llc · since Feb 1, 2017
Douglas Crawford
Platform and operationsDirector of Operations, Bay Area
Jennifer Griffin
Platform and operationsVice President of Finance
Josephine Brysting
Platform and operationsDirector of Operations, Cambridge
Loretta Mcclary
Platform and operationsChief Financial Officer, Bioinnovation Management Llc · since Apr 1, 2022
Mark Byrnes
Platform and operationsChief Operations Officer and Chief Compliance Officer
Michael Taylor
Platform and operationsVenture Operations Associate
Nana Kusi Minkah
Platform and operationsChief Financial Officer
Ulrik B. Nielsen
Platform and operationsAccounting and Operations Associate
Peter Parker
PrincipalPrincipal
5 departed (kept with end dates)
- Anthony S Walsh · Member Of Bioinnovation Capital I, Gp Llc · Jun 1, 2019 to Jul 21, 2021 Inference
- Michael Douglas Taylor · Member Of Bioinnovation Capital I, Gp Llc · Jan 1, 2020 to Mar 29, 2023 Inference
- Robert Glenn Blazej · Member Of Mission Biocapital V Gp Llc · Apr 1, 2020 to Mar 29, 2021 Inference
- Douglas Kingsley Crawford · Managing Member Mission Biocapital V Gp Llc · Apr 1, 2020 to May 18, 2022 Inference
- Peter Parker · Managing Member Of Mission Biocapital V, Gp Llc · Apr 1, 2020 to May 18, 2022 Inference
Investments on record
52 edges, 52 companies, 1 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
33 relationships from shared deals, counted for the whole firm
Avego Management, LLC 2 shared · recurringThird Rock Ventures, LLC. 1 shared · one time · they led 1Ignition Partners 1 shared · one timeService Provider Capital 1 shared · one timeAtropos Capital Management, LLC 1 shared · one timeRA Capital Management, LP 1 shared · one timeForesite Capital 1 shared · one timeGSR Ventures 1 shared · one timeSolari Capital Management LLC 1 shared · one timeMitsui & Co. Global Investment, Inc. 1 shared · one timeCivilization Ventures Management, LLC 1 shared · one timeLifeforce Capital Management, LLC 1 shared · one timeNext Frontier Capital Mc, LLC 1 shared · one timeK50 Ventures 1 shared · one timeSanderling Management Company, LLC 1 shared · one timeQED Investors, LLC 1 shared · one timeMenlo Ventures 1 shared · one timeVivo Capital, LLC 1 shared · one timeTA Associates 1 shared · one timeTanglin Venture Partners Pte. Ltd. 1 shared · one timeHummingbird Ventures V US GP LLC 1 shared · one timeMission Bay Capital 1 shared · one timeSofinnova Investments, Inc. 1 shared · one timeCRV, LLC 1 shared · one timeAdvent Life Sciences LLP 1 shared · one timeThe Column Group 1 shared · one timeClaremont Creek Ventures 1 shared · one timeDecheng Capital LLC 1 shared · one timeWxhv 1 shared · one timeInnovation Endeavors: Reimagining the technical frontier 1 shared · one timePfizer Ventures 1 shared · one timeBioMed Partners 1 shared · one timeGimv 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
17 dated events
- Mar 29, 2023Michael Douglas Taylor (Member Of Bioinnovation Capital I, Gp Llc) no longer on Schedule A of Mission Biocapital
- May 18, 2022Douglas Kingsley Crawford (Managing Member Mission Biocapital V Gp Llc) no longer on Schedule A of Mission Biocapital
- May 18, 2022Mission Biocapital V LP no longer reported on Form ADV by Mission BiocapitalFund no longer reportedFundsInferenceMission Biocapital V LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 18, 2022Peter Parker (Managing Member Of Mission Biocapital V, Gp Llc) no longer on Schedule A of Mission Biocapital
- Apr 1, 2022Loretta Mcclary joined Schedule A of Mission Biocapital as Chief Financial Officer, Bioinnovation Management Llc
- Apr 1, 2022Douglas Kingsley Crawford joined Schedule A of Mission Biocapital as Member, Class A Member Of Bioinnovation Capital I Gp Llc
- Jul 21, 2021Anthony S Walsh (Member Of Bioinnovation Capital I, Gp Llc) no longer on Schedule A of Mission Biocapital
- Mar 29, 2021Robert Glenn Blazej (Member Of Mission Biocapital V Gp Llc) no longer on Schedule A of Mission Biocapital
- Jun 2, 2020Mission Biocapital V LP first reported on Form ADV by Mission Biocapital (Venture Capital Fund)Fund first reported on Form ADVFundsFactMission Biocapital V LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2020Robert Glenn Blazej joined Schedule A of Mission Biocapital as Member Of Mission Biocapital V Gp Llc
- Apr 1, 2020Peter Parker joined Schedule A of Mission Biocapital as Managing Member Of Mission Biocapital V, Gp Llc
- Jan 1, 2020Michael Douglas Taylor joined Schedule A of Mission Biocapital as Member Of Bioinnovation Capital I, Gp Llc
- Dec 1, 2019Steven Webb Tregay joined Schedule A of Bioinnovation Capital as Member Of Bioinnovation Capital I, Gp
- Jun 1, 2019Anthony S Walsh joined Schedule A of Bioinnovation Capital as Member Of Bioinnovation Capital I, Gp
- Feb 1, 2017Christopher Taylor Carlin joined Schedule A of Mission Biocapital as Chief Compliance Officer Of Bioinnovation Management Llc
- Apr 21, 2016Bioinnovation Management LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 21, 2016Bioinnovation Capital I LP first reported on Form ADV by Bioinnovation Management LLC (Venture Capital Fund), GAV $41,310,000Fund first reported on Form ADVFundsFactBioinnovation Capital I LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $186M across 2 vehicles
Evidence
82 observations from 3 sources